Document is current
Any future updates will be listed below
-
Authors
Nehme, Jamil https://orcid.org/0000-0003-2771-2043
Mesilmany, Lina https://orcid.org/0000-0003-2930-115X
Varela-Eirin, Marta
Brandenburg, Simone
Altulea, Abdullah
Lin, Yao
Gaya da Costa, Mariana
Seelen, Marc
Hillebrands, Jan-Luuk
van Goor, Harry
Saab, Raya
Akl, Haidar https://orcid.org/0000-0003-4015-6870
Prevarskaya, Natacha
Farfariello, Valerio https://orcid.org/0000-0003-3918-0793
Demaria, Marco https://orcid.org/0000-0002-8429-4813
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (10989)
Dutch Research Council
Lebanese National Council for Scientific Research
- License Information
-
More Information
Article History
Received: 9 March 2023
Accepted: 5 April 2024
First Online: 9 May 2024
Competing interests
: M.D. is founder and shareholder of Cleara Biotech and an adviser for Oisin Biotechnologies. Neither Cleara Biotech nor Oisin Biotechnologies were involved in the study. The other authors declare no competing interests.
